1. Introduction {#sec1}
===============

Infectious diseases, including tuberculosis (TB), cause major global health problems.^[@ref1]−[@ref5]^ This awareness accompanied by the lobbying of some nongovernmental organizations has fueled the renaissance of the search for new antibiotics.^[@ref5]^ In this scenario, the publication on teixobactin (**1**) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) at the beginning of 2015 by Ling et al. raised a pronounced expectation.^[@ref6]^ Teixobactin is a head to side-chain cyclodepsipeptide that exhibits good activity against Gram-positive bacteria and TB.^[@ref6]−[@ref11]^ At the end of 2015, our group published the first synthesis of an analogue of teixobactin, Arg~10~--teixobactin (**2**) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), where the nonproteinogenic amino acid [l]{.smallcaps}-allo-enduracididine was substituted by arginine.^[@ref7],[@ref12]^

![Structure of teixobactin (**1**) and the Arg~10~--teixobactin analogue (**2**).](ao-2016-00354q_0001){#fig1}

Arg~10~--teixobactin (**2**) exhibits similar biological trends as teixobactin (**1**) by showing better activity against Gram-positive bacteria than against Gram-negative bacteria. However, Arg~10~--teixobactin (**2**) was shown to be 1 order of magnitude less active than the parent compound. In 2016, two groups, Payne and co-workers and Li and co-workers,^[@ref13],[@ref14]^ published the total synthesis of the natural product (**1**).

At a glance, the structure of teixobactin, an 11 amino acid peptide, can be defined as a scaffold formed by a linear segment constituted with seven amino acid residues, which we named tail, followed by a cyclic structure with four residues. In the cycle, a [d]{.smallcaps}-Thr is at the bridgehead linked to an [l]{.smallcaps}-Ile, which contains a guanidine side-chain amino acid, and the neutral alanine completes the sequence. The tail end is an *N*-Me-[d]{.smallcaps}-Phe and contains two more [d]{.smallcaps}-amino acids. Another characteristic feature of this peptide is the presence in total of four isoleucine and three polar uncharged residues (two serine and one glutamine).

Although the structure of this peptide was known only relatively recently, there are already a few reports on its structure activity relationship. In this regard, our group and Singh and co-workers independently found that the activity was lost when the three [d]{.smallcaps}-amino acids in the tail were substituted by the corresponding [l]{.smallcaps}-amino acids (phenylalanine, glutamine, and isoleucine). This was also observed when the *N*-Me-[d]{.smallcaps}-Phe at the *N*-terminal was substituted with *N*-Ac-[d]{.smallcaps}-Phe, indicating the importance of a positive charge at the *N*-terminal.^[@ref8],[@ref10]^

More recently and during the completion of this study, Nowick and co-workers have reported another bioactivity study, employing Arg~10~--teixobactin (**2**) as a reference.^[@ref15]^ The main conclusions of their work are that the Lys~10~--teixobactin (substitution of the arginine by lysine) is more active than (**2**). Furthermore, the absolute stereochemistry is insignificant. Thus, the enantiomer, where [l]{.smallcaps} has been substituted by [d]{.smallcaps} residues and vice versa, maintains the activity. Finally, the residues 1--5 of the tail could be substituted by a dodecanoyl group.

2. Results and Discussion {#sec2}
=========================

In our current efforts to develop a more potent analogue of teixobactin and later to explore the mode of action of this family of compounds, a lysine scan was carried out. Lysine scanning of a peptide involves the preparation of a set of analogues, where each one contains a lysine residue in a different position of the sequence while keeping the same stereochemistry.^[@ref16]^ In contrast to alanine scanning, which is a more frequently used technique for the identification of amino acids that are not key for biological activities, lysine scanning has not been extensively reported in the literature for antimicrobial peptides (AMPs).^[@ref17],[@ref18]^

Lysine scanning could be extremely important to speed up AMP medicinal chemistry programs because it may render analogues with a better potency and is more easily modifiable through the substitution of lysine by other basic residues.^[@ref19]^

In this sense, eight analogues containing [l]{.smallcaps}-Lys at positions 2, 3, 6, 7, 9, and 11 and [d]{.smallcaps}-Lys at positions 4 and 5 were prepared. Because [d]{.smallcaps}-Thr is essential for creating the ester bond and to build up the depsipeptide cycle, the corresponding lysine analogue at the bridgehead position 8 was not prepared. Also, neither the analogue at position 1 (importance was previously established by our group)^[@ref10]^ nor the one at position 10 (reported by the group of Nowick and co-workers)^[@ref15]^ was investigated in this study. The eight lysine analogues covered the substitution of the four hydrophobic isoleucine (represented by the red color in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}), the three polar uncharged residues 2× serine, glutamine(represented by the green color in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}), and the neutral alanine (represented by the yellow color in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) by lysine.

![Illustration of lysine scanning on the Arg~10~--teixobactin analogue.](ao-2016-00354q_0003){#fig2}

[Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} clearly shows that the substitution of four isoleucine (three [l]{.smallcaps}[-]{.smallcaps} and one [d]{.smallcaps}-allo) by lysine led to a total loss of activity. On the other hand, the substitution of the three polar uncharged amino acids, (Ser~3~, Gln~4~, and Ser~7~) and the neutral Ala~9~ maintained or improved the activity in some cases. Thus, these data show that there is a relative balance between the hydrophilic and hydrophobic parts in teixobactin analogues. As shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, introducing a polar positively charged residue into the new analogues instead of a polar uncharged residue improved the activity against some strains in comparison with the reference Arg~10~--teixobactin (**2**). (For example, Lys~3~--Arg~10~--teixobactin shows better activity against the two bacterial strains Bacillus subtilis and Escherichia coli than the reference Arg~10~--teixobactin. Also, it shows minimal activity against Pseudomonas aeruginosa, whereas the reference shows no activity against the same strains). Furthermore, Lys~4~--Arg~10~--teixobactin and Lys~9~--Arg~10~--teixobactin exhibit activity against Staphylococcus aureus and B. subtilis strains close to Arg~10~--teixobactin and better activity against E. coli and P. aeruginosa strains than the reference. This will facilitate the possibility of finding analogues with improved activity by substituting lysine by other basic residues such as arginine.

###### MIC (μg/mL) for Lys~2--11~ Teixobactin Analogues

                                              MIC μg/mL (ATCC strains)                                
  ------------------------------------------- ------------------------------------ -------- --------- ------
  Arg~10~--teixobactin (**2**)^[@ref7]^       2                                    0.5      64        NI
  Lys~2~                                      NI[a](#t1fn1){ref-type="table-fn"}   NI       NI        NI
  Lys~3~                                      4                                    0.25     32        128
  Lys~4~                                      4                                    1        32        128
  Lys~5~                                      NI                                   NI       NI        NI
  Lys~6~                                      NI                                   NI       NI        NI
  Lys~7~                                      32                                   8        256       256
  Lys~9~[b](#t1fn2){ref-type="table-fn"}      6                                    1        50        100
  Lys~11~                                     NI                                   NI       NI        NI
  meropenem[c](#t1fn3){ref-type="table-fn"}   0.0625                               0.0625   0.03125   0.25

NI: no inhibition.

The starting concentration is 100 μg/mL.

Used as controls.

3. Experimental Section {#sec3}
=======================

3.1. Materials {#sec3-1}
--------------

All reagents and solvents were obtained from commercial suppliers and used without further purification. Analytical high-pressure liquid chromatography (HPLC) was performed on an Agilent 1100 system, and the Chemstation software was used for data processing. Buffer A was 0.1% trifluoroacetic acid in H~2~O, and buffer B was 0.1% trifluoroacetic acid in CH~3~CN. Liquid chromatography--mass spectrometry (LC--MS) was performed on a Shimadzu 2020 ultrafiltration-LC--MS using an YMC-Triart C18 (5 μm, 4.6 × 150 mm) column, and data processing was carried out using the Lab Solution software. Buffer A was 0.1% formic acid in H~2~O, and buffer B was 0.1% formic acid in CH~3~CN. Crude peptides were purified with a Shimadzu LC-8A preparative HPLC using a Phenomenex Luna C18(2) 100 Å column (10 μm × 250 mm). High-resolution mass spectrometry (HRMS) was acquired using a Bruker ESI-Q-TOF mass spectrometer in the positive mode. Matrix-assisted laser desorption ionization (MALDI) was performed on a Bruker MALDI-TOF Autoflex SmartBeam II system (Bruker Daltonics, Bremen, Germany) using the MALDI matrix (α-cyano-4-hydroxycinnamic acid).

3.2. Methods {#sec3-2}
------------

The eight analogues were synthesized using the solid-phase peptide synthesis (SPPS) technique as previously described.^[@ref7],[@ref10]^ Succinctly, the synthesis was started by anchoring a residue at position 9 \[Fmoc-Ala-OH or Fmoc-Lys(Boc)-OH in the case of the Lys~9~ analogue\] to a chlorotrityl chloride polystyrene resin (CTC-resin), and then the elongation of the peptide chain was achieved by the use of Fmoc-amino acids until residue at position 6 (isoleucine or lysine in the case of the Lys~6~ analogue, in all cases except in the synthesis where Lys~11~ analogue). Then, the β-hydroxyl functional group of [d]{.smallcaps}-Thr, which had been incorporated without protection, was acylated by Alloc-[l]{.smallcaps}-Ile-OH, followed by the incorporation of Alloc-Arg(Pbf)-OH. Finally, the Fmoc-based synthesis was continued until the incorporation of Boc-*N*-Me-[d]{.smallcaps}-Phe-OH, whereas in the synthesis of the analogue Lys~11~, the Fmoc-SPPS was performed until the incorporation of Boc-*N*-Me-[d]{.smallcaps}-Phe-OH, and then the esterification of the threonine amino acid was carried out by Fmoc-Lys(Boc)-OH followed by the incorporation of Fmoc-Arg(Pbf)-OH.

The cleavage of the semiprotected peptide, having the free α-amino acid group of arginine and the carboxylic group of alanine or lysine in the case of the Lys~9~ analogue, was carried out with 0.1% trifluoroacetic acid (TFA) in dichloromethane followed by cyclization using ((7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate/ethyl cyano(hydroxyimino)acetate/diisopropylethylamine, 3:3:6). The final global deprotection was enabled with TFA/triisopropylsilane/H~2~O (95:2.5:2.5), and the peptides were purified using HPLC and characterized using HRMS (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00354/suppl_file/ao6b00354_si_001.pdf)). The minimum inhibitory concentration (MIC) was determined as previously described, with meropenem as the control (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00354/suppl_file/ao6b00354_si_001.pdf)).^[@ref10]^

4. Conclusions {#sec4}
==============

In conclusion, performing a lysine scan has allowed the identification of the essential residues for maintaining the balance between the hydrophilic and hydrophobic amino acids for the antimicrobial activity of teixobactin analogues. Thus, the substitution of any of the isoleucine residues by lysine rendered the compound with a total loss of activity. Furthermore, the substitution of the three polar uncharged amino acids and alanine by lysine allowed us to sustain the antimicrobial potency and in some cases to improve it. We envisage that the lysine scanning will become a useful tool for the discovery of new AMPs as it has been shown in this study.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.6b00354](http://pubs.acs.org/doi/abs/10.1021/acsomega.6b00354).Synthetic methods, HPLC, HRMS, and MALDI ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00354/suppl_file/ao6b00354_si_001.pdf))
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DIEA

:   diisopropylethylamine

OxymaPure

:   ethyl cyano(hydroxyimino)acetate

PyAOP

:   (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate

TFA

:   trifluoroacetic acid

TIS

:   triisopropylsilane
